Vir Biotechnology, Inc. (VIR)
| Market Cap | 1.48B +76.6% |
| Revenue (ttm) | 65.50M +214.0% |
| Net Income | -442.72M |
| EPS | -3.14 |
| Shares Out | 168.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,714,436 |
| Open | 8.96 |
| Previous Close | 9.09 |
| Day's Range | 8.64 - 8.98 |
| 52-Week Range | 4.16 - 11.66 |
| Beta | 1.70 |
| Analysts | Strong Buy |
| Price Target | 19.43 (+121.05%) |
| Earnings Date | May 6, 2026 |
About VIR
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company’s preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting va... [Read more]
Financial Performance
In 2025, Vir Biotechnology's revenue was $68.56 million, a decrease of -7.61% compared to the previous year's $74.21 million. Losses were -$437.99 million, -16.09% less than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for VIR stock is "Strong Buy." The 12-month stock price target is $19.43, which is an increase of 121.05% from the latest price.
News
Vir Biotechnology Transcript: Bank of America Global Healthcare Conference 2026
Multiple value creation paths are advancing, including a near-term Delta Program, a differentiated oncology platform, and a robust HDV regimen outperforming competitors. Strategic partnerships and a strong cash position support parallel development and targeted commercial build-out.
Vir Biotechnology price target lowered to $23 from $24 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Vir Biotechnology (VIR) to $23 from $24 and keeps an Overweight rating on the shares.
Vir Biotechnology reports Q1 EPS (85c) vs. (88c) last year
“Vir Bio delivered incredible momentum during the first quarter with positive, new VIR-5500 Phase 1 data and execution of a global agreement with Astellas in prostate cancer. The closing of…
Vir Biotechnology Earnings Call Transcript: Q1 2026
Major advances in oncology and hepatitis delta programs, highlighted by a $1.7B Astellas collaboration and strong phase II data for tobevibart plus elebsiran. Cash runway extends into 2H 2028, supporting multiple milestones and disciplined capital allocation.
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the first quarter ended March 31, 2026. “Vir Bio delivered i...
Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the B...
Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, May 6 to provide a corporate upd...
Vir Biotechnology closes global collaboration agreement with Astellas Pharma
Vir Biotechnology (VIR) announced that its global collaboration and licensing agreement with Astellas (ALPMY) announced on February 23 has closed following expiration of the waiting period under the H...
Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its global collaboration and licensing agreement with Astellas announced on February 23, 2026 has closed foll...
Vir Biotechnology announces first patient dosed in Phase 1 trial of VIR-5500
Vir Biotechnology (VIR) announced that the first patient has been dosed in one of three expansion cohorts in the Phase 1 trial evaluating VIR-5500, a prostate-specific membrane antigen-targeted, PRO-X...
Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in one of three expansion cohorts in the Phase 1 trial evaluating VIR-5500, ...
Vir Biotechnology Transcript: Leerink Global Healthcare Conference 2026
The company is advancing a robust immuno-oncology and infectious disease pipeline, highlighted by strong efficacy and safety data for its masked T-cell engager in prostate cancer and a promising dual regimen for hepatitis delta. Strategic partnerships and financing have extended cash runway to 2028.
Vir Biotechnology price target raised to $20 from $15 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Vir Biotechnology (VIR) to $20 from $15 and keeps a Buy rating on the shares. The firm says the “landmark” Astellas collaboration…
Vir Biotechnology Transcript: TD Cowen 46th Annual Health Care Conference
VIR-5500 showed strong efficacy and safety in late-stage prostate cancer, enabling expansion and pivotal trials next year. The Astellas partnership accelerates development with significant financial terms and joint governance. Pipeline and HDV programs advance, with a robust cash position supporting growth.
Vir Biotechnology to Participate in Upcoming Investor Conferences
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the management team will participate in the following investor conferences during the month of Mar...
Vir Biotechnology 17.65M share Secondary priced at $8.50
The deal size was reduced to $150M in common stock from $200M in common stock. Goldman Sachs, Leerink, Evercore ISI and Barclays acted as joint book running managers for the…
Vir Biotechnology Announces Pricing of Public Offering of Common Stock
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing...
Vir Biotechnology announces $200M public offering of common stock
Goldman Sachs & Co. LLC, Leerink Partners, Evercore ISI and Barclays are acting as book-running managers for the offering.
Vir Biotechnology Announces Proposed Public Offering of Common Stock
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing...
Vir Biotechnology price target raised to $30 from $26 at Barclays
Barclays raised the firm’s price target on Vir Biotechnology (VIR) to $30 from $26 and keeps an Overweight rating on the shares.
Vir Biotechnology price target raised to $18 from $14 at Needham
Needham raised the firm’s price target on Vir Biotechnology (VIR) to $18 from $14 and keeps a Buy rating on the shares. Along with its better than expected Q4 results,…
Why Is Vir Biotechnology Stock Up Today?
Vir Biotechnology stock gained greatly on news of a major strategic collaboration.
Vir Biotechnology price target raised to $18 from $12 at Evercore ISI
Evercore ISI analyst Cory Kasimov raised the firm’s price target on Vir Biotechnology (VIR) to $18 from $12 and keeps an Outperform rating on the shares. The Astellas (ALPMY) deal…
Vir Biotechnology price target raised to $17 from $13 at BofA
BofA analyst Alec Stranahan raised the firm’s price target on Vir Biotechnology (VIR) to $17 from $13 and keeps a Buy rating on the shares. Updated Phase 1b data for…
Vir Biotechnology price target raised to $24 from $20 at Morgan Stanley
Morgan Stanley analyst Michael Ulz raised the firm’s price target on Vir Biotechnology (VIR) to $24 from $20 and keeps an Overweight rating on the shares. Phase 1 VIR-5500 data…